Pharma TV spending bounced back with pro sports in August, with AbbVie, Regeneron/Sanofi leading the way – FiercePharma

Call it a fall sports bounce. Maybe not the typical one, but TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.

While news shows are the top pharma mainstay for TV ad buys, sports are another favored category for some drugmakers. In August, for instance, drug brands with broader target audiences bought on National Basketball Association (NBA), National Hockey League (NHL) and Major League Baseball (MLB) programming. Those brandsincluded anti-inflammatory drugs Humira from AbbVie and Dupixent from Sanofi and Regeneron and diabetes treatment Trulicity from Eli Lilly, all of which made the top 10 pharma TV buyers in August.

The pharma industry wasn't the biggest contributor, but it joined the 527 companies thatspent$100 million on national TV ads during games since sports' return in July and August, according to MediaRadar data.

Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure GelMA can help you in your developments.

Indeed, Humira bumped spending across the board in August, tallying$39.9million and a17% increase over July, while Dupxient almost doubled its spending to $21.9 million, up from $11.1 million in July.

The top 10 highest-spending brandslist for August looked similar to that in July, with one notable addition: former big spender Enbrel from Amgen, which made a comeback.Its latest ad doesnt include longtime spokesperson and golfer Phil Mickelson, though;Enbrel last aired TV ads featuring the PGA Tour champ, who suffers from rheumatoid arthritis, in June.

Spending for August was slightly down year-over-year, with the top 10 tallying $148 million compared with$165 million last August. It was right on par with August 2018's total, though, at $149 million. August's spending total also saw anincrease over both July and June, when top 10 pharma brands spent $136 million and $141 million, respectively.

1. Humira Movement: Stayed the same What is it? AbbVie anti-inflammatory drug Total estimated spending: $39.9 million (up from $34.1 million in July) Number of spots: Five (two for arthritis/psoriasis, three for ulcerative colitis/Crohn's) Biggest-ticket ad: Body of Proof: Bicycling, Painting, Traveling (est. $15.2 million)

2. Dupixent Movement: Up from No. 5 What is it? Regeneron and Sanofi's atopic dermatitis and asthma treatment Total estimated spending: $21.9 million (up from $11.1 million in July) Number of spots: Three (one for atopic dermatitis, two for asthma) Biggest-ticket ad: Roll Up Your Sleeves: Financial Situation (est. $11.8 million)

3. Descovy Movement: Up from No. 6 What is it? Gilead Sciences next-gen PrEP HIV drug Total estimated spending: $15.9 million (up from $10.7 million in July) Number of spots: One Biggest-ticket ad: Prep Up

4. Trulicity Movement: Up from No. 7 What is it? Eli Lilly GLP-1 diabetes drug Total estimated spending: $14.1 million (up from $10.2 million in July) Number of spots: Three Biggest-ticket ad: Power: Day of Work: $25 Savings (est. $12.6 million)

5. Ocrevus Movement: Down from No. 2 What is it? Roche multiple sclerosis drug Total estimated spending: $11.3 million (down from $16.2 million in July) Number of spots: Two Biggest-ticket ad: Dear MS" (est. $7.4 million)

*Ad not available on iSpot.tv

6. Eliquis Movement: Down from No. 4 What is it? Pfizer and Bristol Myers Squibb next-gen anticoagulant Total estimated spending: $10.3 million (down from $13.2 million in July) Number of spots: Four Biggest-ticket ad: Whats Next: Flower (est. $3.5 million)

7. Xeljanz Movement: Down from No. 3 What is it? Pfizer oral rheumatoid arthritis therapy Total estimated spending: $9.8 million (down from $15.5 million in July) Number of spots: Three Biggest-ticket ad: "Needles: Sewing" (est. $4.9 million)

8. Ibrance Movement: Not on list last month What is it? Pfizers metastatic breast cancer fighter Total estimated spending: $8.7 million Number of spots: One Biggest-ticket ad: Your Moment: Scrapbook

9. Skyrizi Movement: Down from No. 8 What is it? AbbVie IL-23 next-gen psoriasis treatment Total estimated spending: $8.5 million (down from $10 million in July) Number of spots: Four Biggest-ticket ad: Swimming (est. $2.5 million)

10. Enbrel Movement: Not on list last month What is it? Amgens TNF inhibitor to treat autoimmune diseases Total estimated spending: $7.5 million Number of spots: One Biggest-ticket ad: Leah

Continued here:
Pharma TV spending bounced back with pro sports in August, with AbbVie, Regeneron/Sanofi leading the way - FiercePharma